BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk Melanoma and PD-L1 <1%

BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk Melanoma and PD-L1

Shots:

  • The P-III CheckMate -915 study involves assessing of Opdivo (240mg, IV, q2w) in combination with Yervoy (1 mg/kg, q6w) vs Opdivo (480mg, q4w) as monothx. as the adjuvant therapy in 1,943 patients who have had complete surgical removal of stage IIIb/c/d or stage IV melanoma
  • The P-III CheckMate -915 study did not meet its 1EPs of recurrence-free survival in patients with tumors PD-L1 <1% expression. The study will continue to assess 1EPs of RFS in IIT population, recommended by the Data Monitoring Committee
  • Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response while Yervoy is mAb targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) thus blocking its interaction with its ligands, CD80/CD86

Click here to­ read full press release/ article | Ref: BMS | Image: Dawson Design